StockNews.com Initiates Coverage on Akari Therapeutics (NASDAQ:AKTX)

Analysts at StockNews.com began coverage on shares of Akari Therapeutics (NASDAQ:AKTX) in a research report issued to clients and investors on Wednesday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.

Akari Therapeutics Trading Down 2.3 %

NASDAQ:AKTX opened at $1.27 on Wednesday. Akari Therapeutics has a one year low of $0.90 and a one year high of $4.40. The stock has a 50-day simple moving average of $2.20 and a 200 day simple moving average of $2.83.

Akari Therapeutics Company Profile

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration.